Clinical Trial Update: To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions [Phase 1]

View source ↗

Summary

A Phase 1 study conducted by Sandoz to assess the relative bioavailability of diclofenac sodium 50 mg enteric-coated tablets under non-fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation

Drugs mentioned

• Diclofenac Sodium 50 mg Enteric-Coated Tablets (diclofenac sodium)

Snippet

Sponsor: Sandoz | Conditions: Inflammation | Phase 1 | Status: COMPLETED